La Ingeniería Automotriz clave para el desarrollo sostenible de Ecuador

El presente texto es una contribución al desarrollo de la sostenibilidad ecuatoriana y mantiene el debate sobre temas del estudio de la Ingeniería Automotriz. El mérito del libro radica en una triple condición: alimenta la investigación académica ecuatoriana, contribuye a llenar el vacío de producción científica automotriz direccionada a las necesidades del Ecuador y reconoce el esfuerzo de los investigadores que se dedican a la producción académica técnica. La Universidad Politécnica Salesiana —en su sede Guayaquil— realizó en 2018, las Segundas Jornadas Científicas de Ingeniería Automotriz; este texto es el producto final de ese evento académico, cuyas memorias técnicas son constituidas por ocho resultados de investigaciones en Ingeniería Automotriz que aportarán desarrollo sostenible al Ecuador en áreas como: el diseño, el control de contaminación, la eficiencia energética y la movilidad. Este recorrido por varias ramas de la Ingeniería Automotriz muestra al lector múltiples aplicaciones y cambios de paradigmas en la industria; no somos solamente consumidores de tecnología, somos también productores de la misma. Este texto da cuenta del desarrollo de la industria automotriz ecuatoriana. Ing. Renato Fierro J. MSc

Desarrollo tecnológico en ingeniería automotriz

El proceso de investigación y desarrollo tecnológico está directamente relacionado con una adecuada metodología de procesos industriales, que cada vez son más exigentes en competitividad, eficiencia energética y de normativas ambientales. Este libro contempla resultados de un proceso de investigación y desarrollo de nuevas técnicas aplicadas en el campo de la Ingeniería Automotriz desde cuatro aristas: eficiencia energética y contaminación ambiental, planificación del transporte, ingeniería del mantenimiento aplicada al transporte y desagregación tecnológica. Este libro conmemora 20 años de formación universitaria salesiana en el sector de transporte y recoge las experiencias y resultados obtenidos asociados con el desarrollo tecnológico en ingeniería automotriz. Para lograr este objetivo, se ha convocado a la comunidad científica, académica y profesionales de la industria automotriz a participar en la publicación. Cada capítulo fue sometido a revisión, evaluación y aprobación por un comité científico altamente calificado, proveniente de seis países: Colombia, Ecuador, España, Guinea Ecuatorial, México y Venezuela. Este trabajo ha sido posible gracias al gran apoyo de la Universidad Politécnica Salesiana (UPS sede Cuenca), Ecuador y Universidad de Los Andes (ULA)

Biosafety at home: How to translate biomedical laboratory safety precautions for everyday use in the context of COVID-19

Copyright © 2020 by The American Society of Tropical Medicine and Hygiene Population adoption of social distancing measures during the COVID-19 pandemic is at times deficient, increasing the risk of SARS-CoV-2 transmission. Healthcare workers and those living in areas of intense transmission may benefit from implementing biosafety measures in their daily lives. A mixed-methods approach, combining components of single negotiation text and the Delphi method, was used to create a COVID-19 biosafety-at-home protocol. A consensus building coordinator liaised with 12 experts to develop the protocol over 11 iterations. Experts had more than 200 years of combined experience in epidemiology, virology, infectious disease prevention, and public health. A flyer, created from the final protocol, was professionally designed and initially distributed via social media and institutional websites/emails in Ecuador beginning on May 2, 2020. Since then, it has been distributed in other countries, reaching ∼7,000 people. Translating research laboratory biosafety measures for the home/street environment might be challenging. The biosafety-at-home flyer addresses this challenge in a user-friendly format

Apixaban versus warfarin in patients with atrial fibrillation

BACKGROUND: Vitamin K antagonists are highly effective in preventing stroke in patients with atrial fibrillation but have several limitations. Apixaban is a novel oral direct factor Xa inhibitor that has been shown to reduce the risk of stroke in a similar population in comparison with aspirin. METHODS: In this randomized, double-blind trial, we compared apixaban (at a dose of 5 mg twice daily) with warfarin (target international normalized ratio, 2.0 to 3.0) in 18,201 patients with atrial fibrillation and at least one additional risk factor for stroke. The primary outcome was ischemic or hemorrhagic stroke or systemic embolism. The trial was designed to test for noninferiority, with key secondary objectives of testing for superiority with respect to the primary outcome and to the rates of major bleeding and death from any cause. RESULTS: The median duration of follow-up was 1.8 years. The rate of the primary outcome was 1.27% per year in the apixaban group, as compared with 1.60% per year in the warfarin group (hazard ratio with apixaban, 0.79; 95% confidence interval [CI], 0.66 to 0.95; P<0.001 for noninferiority; P = 0.01 for superiority). The rate of major bleeding was 2.13% per year in the apixaban group, as compared with 3.09% per year in the warfarin group (hazard ratio, 0.69; 95% CI, 0.60 to 0.80; P<0.001), and the rates of death from any cause were 3.52% and 3.94%, respectively (hazard ratio, 0.89; 95% CI, 0.80 to 0.99; P = 0.047). The rate of hemorrhagic stroke was 0.24% per year in the apixaban group, as compared with 0.47% per year in the warfarin group (hazard ratio, 0.51; 95% CI, 0.35 to 0.75; P<0.001), and the rate of ischemic or uncertain type of stroke was 0.97% per year in the apixaban group and 1.05% per year in the warfarin group (hazard ratio, 0.92; 95% CI, 0.74 to 1.13; P = 0.42). CONCLUSIONS: In patients with atrial fibrillation, apixaban was superior to warfarin in preventing stroke or systemic embolism, caused less bleeding, and resulted in lower mortality. Copyright © 2011 Massachusetts Medical Society. All rights reserved

Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: A subgroup analysis of the ARISTOTLE trial

Background: In the ARISTOTLE trial, the rate of stroke or systemic embolism was reduced by apixaban compared with warfarin in patients with atrial fibrillation (AF). Patients with AF and previous stroke or transient ischaemic attack (TIA) have a high risk of stroke. We therefore aimed to assess the efficacy and safety of apixaban compared with warfarin in prespecified subgroups of patients with and without previous stroke or TIA. Methods: Between Dec 19, 2006, and April 2, 2010, patients were enrolled in the ARISTOTLE trial at 1034 clinical sites in 39 countries. 18 201 patients with AF or atrial flutter were randomly assigned to receive apixaban 5 mg twice daily or warfarin (target international normalised ratio 2·0-3·0). The median duration of follow-up was 1·8 years (IQR 1·4-2·3). The primary efficacy outcome was stroke or systemic embolism, analysed by intention to treat. The primary safety outcome was major bleeding in the on-treatment population. All participants, investigators, and sponsors were masked to treatment assignments. In this subgroup analysis, we estimated event rates and used Cox models to compare outcomes in patients with and without previous stroke or TIA. The ARISTOTLE trial is registered with ClinicalTrials.gov, number NTC00412984. Findings: Of the trial population, 3436 (19%) had a previous stroke or TIA. In the subgroup of patients with previous stroke or TIA, the rate of stroke or systemic embolism was 2·46 per 100 patient-years of follow-up in the apixaban group and 3·24 in the warfarin group (hazard ratio [HR] 0·76, 95% CI 0·56 to 1·03); in the subgroup of patients without previous stroke or TIA, the rate of stroke or systemic embolism was 1·01 per 100 patient-years of follow-up with apixaban and 1·23 with warfarin (HR 0·82, 95% CI 0·65 to 1·03; p for interaction=0·71). The absolute reduction in the rate of stroke and systemic embolism with apixaban versus warfarin was 0·77 per 100 patient-years of follow-up (95% CI -0·08 to 1·63) in patients with and 0·22 (-0·03 to 0·47) in those without previous stroke or TIA. The difference in major bleeding with apixaban compared with warfarin was 1·07 per 100 patient-years (95% CI 0·09-2·04) in patients with and 0·93 (0·54-1·32) in those without previous stroke or TIA. Interpretation: The effects of apixaban versus warfarin were consistent in patients with AF with and without previous stroke or TIA. Owing to the higher risk of these outcomes in patients with previous stroke or TIA, the absolute benefits of apixaban might be greater in this population. Funding: Bristol-Myers Squibb and Pfizer. © 2012 Elsevier Ltd